logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Mozart Therapeutics Raises $25 Million In Expanded Series A Financing To Support Clinical Development Of First-In-Class Cd8 Treg Modulators For The Treatment Of Autoimmune Diseases

Jun 07, 2023•over 2 years ago

Amount Raised

$25 Million

Round Type

series a

SeattleOtherHealth Care

Investors

Marie Claire PeakmanAlexandria Venture InvestmentsAltitude Life Science VenturesLeaps By BayerMrl Ventures FundEli Lilly & CompanySofinnova PartnersArch Venture PartnersUpmc EnterprisesOno Venture InvestmentAbb Vie VenturesPfizer VenturesJasmina Marjanovic, Ph D, Director Abb Vie VenturesMarie Claire Peakman, Ph D, Partner, Pfizer Ventures

Description

Mozart Therapeutics, a leading developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory diseases, today announced it has raised $25 million from new investors in a Series A extension, bringing the total raise to $80 million. The proceeds will be used to advance the company's lead candidate, MTX-101, into first-in-human clinical trials and to support pipeline expansion.

Company Information

Company

Mozart Therapeutics

Location

Seattle, Washington, United States

About

Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory immune pathway. The therapeutic focus of Mozart's lead program is autoimmune mediated gastro-intestinal disorders. The company is headquartered in Seattle, WA.

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech